Biomerica (BMRA) Asset Writedowns and Impairment (2010 - 2026)
Biomerica (BMRA) reported Asset Writedowns and Impairment of -$143000.0 for Q1 2026, down 169.81% on a YoY basis from $204837.8 in Q1 2025, and down 326.98% sequentially from $63000.0 in Q4 2025.
Biomerica (BMRA) Asset Writedowns and Impairment (2010 - 2026) Analysis & Trends
Biomerica (BMRA) has 17 years of Asset Writedowns and Impairment data on file, last reported at -$143000.0 in Q1 2026.
- For the quarter ending Q1 2026, Asset Writedowns and Impairment fell 169.81% year-over-year to -$143000.0; the trailing twelve-month figure through Feb 2026 stood at -$20000.0 (up 71.01% YoY), and the FY2025 full-year result was $8000.0, up 103.9% from the prior year.
- Asset Writedowns and Impairment slipped to -$143000.0 in Q1 2026, from $63000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $1.1 million in Q1 2022 to a low of -$954805.0 in Q2 2022.
- A 5-year average of -$18727.2 and a median of -$4000.0 in 2024 frame the typical range for Asset Writedowns and Impairment.
- Across the five-year window, Asset Writedowns and Impairment tumbled 607.89% in 2022 and jumped 1675.0% in 2025, its largest moves.
- Tracing BMRA's Asset Writedowns and Impairment over 5 years: stood at $139000.0 in 2022, then fell by 4.32% to $133000.0 in 2023, then slumped by 103.01% to -$4000.0 in 2024, then jumped by 1675.0% to $63000.0 in 2025, then tumbled by 326.98% to -$143000.0 in 2026.
- Business Quant data shows BMRA's Asset Writedowns and Impairment at -$143000.0 in Q1 2026, $63000.0 in Q4 2025, and $7000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 184.32 Bn | 177.02 Bn | 6.27 Bn |
| 2 | Stryker | 128.89 Bn | 126.01 Bn | 3.81 Bn |
| 3 | Medtronic | 108.88 Bn | 99.66 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.65 Bn | 67.20 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 47.43 Bn | 43.76 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 28.48 Bn | 26.19 Bn | 1.98 Bn |
| 7 | Dexcom | 28.45 Bn | 27.33 Bn | 750.30 Mn |
| 8 | Smith & Nephew | 26.98 Bn | 26.40 Bn | - |
| 9 | Koninklijke Philips | 25.54 Bn | 22.42 Bn | 2.07 Bn |
| 10 | Biomerica | 4.88 Mn | 3.54 Mn | -44,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -143,000.00 |
| Feb 28, 2026 | -143,000.00 |
| Nov 30, 2025 | 63,000.00 |
| Nov 30, 2025 | 63,000.00 |
| Aug 31, 2025 | 7,000.00 |
| Aug 31, 2025 | 7,000.00 |
| May 31, 2025 | 53,000.00 |
| May 31, 2025 | 53,000.00 |
| Feb 28, 2025 | -53,000.00 |
| Feb 28, 2025 | -53,000.00 |
| Nov 30, 2024 | -4,000.00 |
| Nov 30, 2024 | -4,000.00 |
| Aug 31, 2024 | 12,000.00 |
| Aug 31, 2024 | 12,000.00 |
| May 31, 2024 | -24,000.00 |
| May 31, 2024 | -24,000.00 |
| Feb 29, 2024 | -174,000.00 |
| Feb 29, 2024 | -174,000.00 |
| Nov 30, 2023 | 133,000.00 |
| Nov 30, 2023 | 133,000.00 |